ConvaTec announces the release of ConvaMax™


14 January 2020


ConvaTec Group Plc (“ConvaTec”), a leading global medical technology company, announced January 14th 2020 the release of ConvaMax™ the NEW superabsorber dressing distributed by ConvaTec. The global superabsorber market is currently greater than $100m growing at +7% 1

ConvaMax™ superabsorber wound dressing is used for the management of highly exuding wounds, including leg ulcers, pressure ulcers, diabetic foot ulcers and dehisced surgical wounds.

ConvaMax™ superabsorber manages excess moisture to help protect skin integrity2. Where there is a real risk of skin damage due to high levels of exudate, ConvaMax™ is ideal. It is available in non-adhesive and silicone adhesive forms, providing complete flexibility to support your care protocol. This includes under compression bandaging or with an additional primary dressing.

At ConvaTec, we are committed to innovating our product pipeline providing both our customers and patients with further differentiated technologies and complete solutions for managing chronic and acute wounds. 

David Shepherd, President of ConvaTec’s Advanced Wound Care Franchise, believes that: “ConvaMax™ will add to our already strong wound portfolio. ConvaMax™ gives us a great product for highly exuding wounds; the reception from our sales and marketing colleagues and the expert customers who have seen the dressings already has been extremely positive, and we look forward to a similar reaction as countries begin to launch the product in the coming months.”

  1. Full year Sales 2018 Smartrak 2019
  2. World Union of Wound Healing Societies (2019) Consensus Document. Wound exudate: effective assessment and management Wounds International. Available at:

For more information please call.



Analysts and Investors 




Mark Reynolds, Director Investor Relations

+44 (0)7551 036625













Charles Ryland/Chris Lane/Vicky Hayns                      

+44 (0)207 466 5000











About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. 

Cookies are needed for this website to work optimally. They also help us to know a little bit about how you use our website, which improves the browsing experience.  Cookies on this site are used for traffic measurement and optimisation of page content only. By continuing to browse on this website, you indicate your consent to the use of cookies.  You may block the use of cookies by following the "How to block and avoid cookies" instructions

Learn more about our Cookie policy